DexTech Medical announces upcoming multiple myeloma study
The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the Medical Products Agency on August 10, 2022. The study will include 20 patients and be conducted at 4-5 hospitals in Sweden and other Nordic countries. Studyn is expected to start in Q1 2023 and be completed during Q4, 2024. Principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Division of Hematology/HERM, Karolinska University Hospital, Huddinge. The main blood markers will be analyzed at the Central Laboratory, Karolinska University